Barclays Issues Positive Forecast for Tandem Diabetes Care (NASDAQ:TNDM) Stock Price

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective boosted by Barclays from $18.00 to $20.00 in a research report report published on Friday,Benzinga reports. Barclays currently has an equal weight rating on the medical device company’s stock.

Several other brokerages have also issued reports on TNDM. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Tuesday, September 8th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $26.00 price objective (down from $30.00) on shares of Tandem Diabetes Care in a report on Friday, August 7th. Oppenheimer reiterated an “outperform” rating on shares of Tandem Diabetes Care in a research report on Friday, August 7th. Citigroup decreased their target price on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 30th. Finally, Truist Financial lowered their target price on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $27.18.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock traded down $1.08 during trading hours on Friday, hitting $16.91. The stock had a trading volume of 5,879,270 shares, compared to its average volume of 2,236,256. The company has a 50-day moving average of $17.65 and a two-hundred day moving average of $18.88. The company has a quick ratio of 2.65, a current ratio of 3.18 and a debt-to-equity ratio of 4.62. The company has a market cap of $1.18 billion, a PE ratio of -23.49 and a beta of 1.59. Tandem Diabetes Care has a fifty-two week low of $12.26 and a fifty-two week high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.15. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The company had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. During the same quarter last year, the company earned ($0.31) EPS. The company’s quarterly revenue was up 13.8% on a year-over-year basis. On average, equities research analysts anticipate that Tandem Diabetes Care will post -0.66 EPS for the current fiscal year.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the completion of the transaction, the director directly owned 24,434 shares in the company, valued at $467,911.10. This represents a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tandem Diabetes Care

Institutional investors and hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC increased its position in shares of Tandem Diabetes Care by 157.4% during the 2nd quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company’s stock worth $51,058,000 after purchasing an additional 2,068,838 shares in the last quarter. Defilade Capital Management L.P. acquired a new stake in Tandem Diabetes Care during the 1st quarter valued at $14,606,000. Quantinno Capital Management LP raised its position in Tandem Diabetes Care by 123.5% in the 1st quarter. Quantinno Capital Management LP now owns 653,870 shares of the medical device company’s stock valued at $12,535,000 after purchasing an additional 361,361 shares during the last quarter. First Trust Advisors LP acquired a new position in Tandem Diabetes Care in the first quarter worth $6,570,000. Finally, Principal Financial Group Inc. boosted its stake in Tandem Diabetes Care by 2.2% in the first quarter. Principal Financial Group Inc. now owns 331,541 shares of the medical device company’s stock worth $6,356,000 after purchasing an additional 7,279 shares in the last quarter.

More Tandem Diabetes Care News

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Third-quarter revenue was $283.7 million, up 13.8% year over year and above analyst expectations of $265.85 million. The loss of $0.10 per share was also narrower than the consensus loss of roughly $0.25. Gross margin improved to 57%, up 2.7 percentage points year over year. Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Tandem forecast 2026 sales of $1.065 billion to $1.085 billion, providing investors with a full-year revenue outlook. Tandem outlines 2026 sales range as CEO transition is set
• Neutral Sentiment: Jeannette Bankes was named president and CEO, succeeding John Sheridan, who is expected to retire at the end of 2026. The planned handover offers continuity but adds a leadership transition for investors to monitor. Tandem names Jeannette Bankes CEO
• Neutral Sentiment: Analyst actions were mixed: Barclays raised its target from $18 to $20 but kept an Equal Weight rating, while Wells Fargo lowered its target from $27 to $25 and maintained Overweight. Both targets remain above the cited $16.91 share price. Barclays rating information Wells Fargo target revision
• Negative Sentiment: Despite improved results, Tandem remains loss-making, with a negative net margin. Continued losses could limit how much investors reward revenue and margin progress. Tandem reports third-quarter loss

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.